- Home
- EDN vs CRGX Comparison
EDN vs CRGX Comparison
Compare EDN & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDN
- CRGX
- Stock Information
- Founded
- EDN 1992
- CRGX 2021
- Country
- EDN Argentina
- CRGX United States
- Employees
- EDN 4642
- CRGX N/A
- Industry
- EDN Electric Utilities: Central
- CRGX
- Sector
- EDN Utilities
- CRGX
- Exchange
- EDN Nasdaq
- CRGX Nasdaq
- Market Cap
- EDN 1.2B
- CRGX 190.0M
- IPO Year
- EDN 2007
- CRGX 2023
- Fundamental
- Price
- EDN $26.17
- CRGX $4.40
- Analyst Decision
- EDN
- CRGX Hold
- Analyst Count
- EDN 0
- CRGX 7
- Target Price
- EDN N/A
- CRGX $4.67
- AVG Volume (30 Days)
- EDN 85.9K
- CRGX 527.8K
- Earning Date
- EDN 08-05-2025
- CRGX 08-11-2025
- Dividend Yield
- EDN N/A
- CRGX N/A
- EPS Growth
- EDN N/A
- CRGX N/A
- EPS
- EDN 0.21
- CRGX N/A
- Revenue
- EDN $2,097,707,542.00
- CRGX N/A
- Revenue This Year
- EDN $51.74
- CRGX $57.81
- Revenue Next Year
- EDN N/A
- CRGX N/A
- P/E Ratio
- EDN $6.50
- CRGX N/A
- Revenue Growth
- EDN 37.57
- CRGX N/A
- 52 Week Low
- EDN $13.78
- CRGX $3.00
- 52 Week High
- EDN $51.69
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- EDN 33.91
- CRGX 55.41
- Support Level
- EDN $26.00
- CRGX $4.09
- Resistance Level
- EDN $27.98
- CRGX $4.31
- Average True Range (ATR)
- EDN 1.50
- CRGX 0.19
- MACD
- EDN -0.20
- CRGX -0.01
- Stochastic Oscillator
- EDN 2.16
- CRGX 61.61
About EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.